Document is current
Any future updates will be listed below
-
Authors
Shiota, Masaki
Matsubara, Nobuaki
Kato, Taigo
Eto, Masatoshi
Osawa, Takahiro
Abe, Takashige
Shinohara, Nobuo
Nishimoto, Koshiro
Yasumizu, Yota
Tanaka, Nobuyuki
Oya, Mototsugu
Fujisawa, Takao
Horasawa, Satoshi
Nakamura, Yoshiaki
Yoshino, Takayuki
Nonomura, Norio
-
Funding
Funding for this research was provided by:
SCRUM JAPAN funds
- License Information
-
More Information
Article History
Received: 29 November 2023
Revised: 10 February 2024
Accepted: 18 February 2024
First Online: 3 April 2024
Conflict of interest
: M. Shiota received honoraria from Janssen Pharmaceutical, AstraZeneca, Astellas Pharma, Sanofi, and Bayer and research funding support from Daiichi Sankyo. N. Matsubara received honoraria from Sanofi, and research funding from Janssen, AstraZeneca, Bayer, Roche, MSD, Taiho, Astellas, Amgen, Eisai, Eli Lilly, PRA Health Science, Takeda, Pfizer, Seagen and Chugai. M. Eto received honoraria from Takeda Pharmaceutical, Janssen Pharmaceutical, AstraZeneca, and Astellas Pharma and research funding support from Astellas Pharma, Sanofi, and Takeda Pharmaceutical. N. Nonomura received honoraria from Takeda Pharmaceutical, Janssen Pharmaceutical, AstraZeneca, Merck Biopharma, Ono Pharmaceutical, and Bristol Myers Squibb. M. Shiota is an Associate Editor at BJC Reports. He was not involved in any aspect of handling of this manuscript or any editorial decisions.
: The SCRUM-Japan MONSTAR SCREEN study was approved by the Institutional Review Board of each participating institution and registered at the University Hospital Medical Information Network (UMIN) Clinical Trials Registry (protocol nos. UMIN000036749). All participants provided written informed consent.
